Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 55
Filter
1.
Clin Hemorheol Microcirc ; 76(2): 309-316, 2020.
Article in English | MEDLINE | ID: mdl-32925010

ABSTRACT

Thrombotic events result from different pathologies and are the underlying causes of severe diseases like stroke or myocardial infarction. Recent basic research now revealed a link between food uptake, food conversion and gut metabolism. Gut microbial production of trimethylamine N-oxide (TMAO) from dietary nutrients like choline, lecithin and L-carnitine was associated with the development of cardiovascular diseases. Within this review we give a systematic overview about the influence of TMAO on blood components like platelets and endothelial cells which both are involved as key players in thrombotic processes. In summary, a mechanistic correlation between the gut microbiome, TMAO and cardiovascular diseases becomes obvious and emphasizes to the significance of the intestinal microbiome.


Subject(s)
Blood Platelets/drug effects , Endothelial Cells/drug effects , Gastrointestinal Microbiome/drug effects , Methylamines/chemistry , Animals , Humans , Mice
2.
Clin Hemorheol Microcirc ; 75(1): 7-11, 2020.
Article in English | MEDLINE | ID: mdl-32568187

ABSTRACT

There is growing evidence that COVID-19 not only affects the lungs but beyond that the endothelial system. Recent studies showed that this can lead to microcirculatory impairments and in consequence to functional disorders of all inner organs. The combination of endothelial dysfunction with a generalized inflammatory state and complement elements may together contribute to the overall pro-coagulative state described in COVID-19 patients leading to venular as well as to arteriolar occlusions.


Subject(s)
Betacoronavirus/pathogenicity , Coronavirus Infections/pathology , Endothelium, Vascular/virology , Pneumonia, Viral/pathology , COVID-19 , Coronavirus Infections/virology , Endothelium, Vascular/pathology , Humans , Pandemics , Pneumonia, Viral/virology , SARS-CoV-2
4.
Clin Hemorheol Microcirc ; 75(1): 13-17, 2020.
Article in English | MEDLINE | ID: mdl-32538831

ABSTRACT

Some months ago, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) broke out in Wuhan, China, and spread rapidly around the world. Some states, such as the Netherlands, Germany, Great Britain, Sweden and the USA initially focused on keeping the restrictions for economy and society as low as possible. The responsible authorities were of the opinion - and still are e.g. in Sweden - that it is sufficient enough to protect particularly vulnerable persons such as the elderly or people with pre-existing conditions. The idea behind this is that as soon as 60 to 70 percent of the population is infected with a pathogen, a so-called "herd immunity" has developed. However, the increasing numbers of deaths and modelling studies showed the expected overload of the hospitals. Therefore, most countries decided for a temporary lockdown with the exception of Sweden.Based on the number of the total population, three times more people died from COVID-19 in Sweden (2679 deaths per 10 million inhabitants) compared to Germany (6848 deaths per 80 million inhabitants). The comparison Sweden versus Taiwan is even worse because 1072 times more people died in Sweden based on the number of the population (6 deaths per 24 million inhabitants).In the face of the lack of an antiviral treatment and the lack of a protective vaccine one must state Taiwan has made the best out of the pandemic situation whereas Sweden failed completely.


Subject(s)
Coronavirus Infections/immunology , Pneumonia, Viral/immunology , Betacoronavirus/immunology , Betacoronavirus/isolation & purification , COVID-19 , Coronavirus Infections/pathology , Coronavirus Infections/prevention & control , Coronavirus Infections/therapy , Female , Humans , Immunity, Herd , Male , Pandemics/prevention & control , Pneumonia, Viral/pathology , Pneumonia, Viral/prevention & control , Pneumonia, Viral/therapy , SARS-CoV-2
5.
Clin Hemorheol Microcirc ; 74(4): 363-372, 2020.
Article in English | MEDLINE | ID: mdl-32390611

ABSTRACT

BACKGROUND: In the early phase of the COVID-19 pandemic Germany missed to set up efficient containment measures. Consequently, the number of cases increased exponentially until a lockdown was implemented to suppress the spread of SARS-CoV-2. Fortunately, Germany has a high capability for coronavirus lab testing and more than 30,000 ICU beds. These capabilities and the lockdown turned out to be an advantage to combat the pandemic and to prevent a health-system overload. AIM: The aim was to predict the plateau day of SARS-CoV-2 infections or deaths. RESULTS: The effect on the viral spread of the German measures taken and the impact on the peak of new infection cases is shown. By normalizing daily case numbers, the plateau day of the current outbreak in Germany could be calculated to be reached at April 12, 2020 (day 103 of 2020). CONCLUSION: Normalized case number curves are helpful to predict the time point at which no further new infections will occur if the epidemic situation remains stable. Upon reaching the plateau day during a lockdown phase, a residual time-period of about 2-3 weeks can be utilized to prepare a safe unlocking period. As can be learned from Asian countries such as South Korea and Taiwan there must be strict rules to keep the risk of infection low. Those include social distancing, face mask wearing in combination with digital contact tracing and serosurveillance studies. Following those rules, a safe dance around the infection curve allows to keep the population at a reduced infection rate.


Subject(s)
Communicable Disease Control/methods , Coronavirus Infections/epidemiology , Coronavirus Infections/therapy , Pneumonia, Viral/epidemiology , Pneumonia, Viral/therapy , Betacoronavirus , COVID-19 , China/epidemiology , Coronavirus Infections/prevention & control , Disease Outbreaks , Germany/epidemiology , Humans , Infectious Disease Medicine/trends , Intensive Care Units , Linear Models , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Quarantine , SARS-CoV-2 , World Health Organization
6.
Monatsschr Kinderheilkd ; 168(6): 488-501, 2020.
Article in German | MEDLINE | ID: mdl-32292213

ABSTRACT

In December 2019 a new human coronavirus emerged in Wuhan, China, which is known as SARS-CoV­2. The clinical course of the disease known as coronavirus disease 2019 (COVID-19) ranges from mild respiratory symptoms to severe lung failure. The virus is currently rapidly spreading around the world and pushing health systems to the limits of their capacity due to the exponential increase in the number of cases. The origin of SARS-CoV­2 lies in the bat coronavirus pool and has now emerged in the human population due to interspecies transmission. Molecular diagnostic methods have been established in a very short time and a number of clinical studies on the effectiveness of different antiviral drugs are ongoing. The development of a vaccine using different approaches is also under investigation.Considering the high number of cases and mortality rates of up to 9% there is an urgent need for action. This article summarizes the current state of knowledge on human coronaviruses with a strong focus on the current data on SARS-CoV­2. Due to the daily changing level of knowledge, the article reflects the status up to 21 March 2020.

7.
RSC Adv ; 8(36): 20124-20130, 2018 May 30.
Article in English | MEDLINE | ID: mdl-35541671

ABSTRACT

To improve detection sensitivity, molecular diagnostics require preconcentration of low concentrated samples followed by rapid nucleic acid extraction. This is usually achieved by multiple centrifugation, lysis and purification steps, for instance, using chemical reagents, spin columns or magnetic beads. These require extensive infrastructure as well as time consuming manual handling steps and are thus not suitable for point of care testing (POCT). To overcome these challenges, we developed a microfluidic chip combining free-flow electrophoretic (FFE) preconcentration (1 ml down to 5 µl) and thermoelectric lysis of bacteria as well as purification of nucleic acids by gel-electrophoresis. The integration of these techniques in a single chip is unique and enables fast, easy and space-saving sample pretreatment without the need for laboratory facilities, making it ideal for the integration into small POCT devices. A preconcentration efficiency of nearly 100% and a lysis/gel-electrophoresis efficiency of about 65% were achieved for the detection of E. coli. The genetic material was analyzed by RT-qPCR targeting the superfolder Green Fluorescent Protein (sfGFP) transcripts to quantify mRNA recovery and qPCR to determine DNA background.

8.
RSC Adv ; 8(47): 26817, 2018 Jul 24.
Article in English | MEDLINE | ID: mdl-35544022

ABSTRACT

[This corrects the article DOI: 10.1039/C8RA02177E.].

9.
Anal Chem ; 88(1): 898-905, 2016 Jan 05.
Article in English | MEDLINE | ID: mdl-26624222

ABSTRACT

This work presents an on-chip isothermal nucleic acid amplification test (iNAAT) for the multiplex amplification and detection of viral and bacterial DNA by a flow-based chemiluminescence microarray. In a principle study, on-chip recombinase polymerase amplification (RPA) on defined spots of a DNA microarray was used to spatially separate the amplification reaction of DNA from two viruses (Human adenovirus 41, Phi X 174) and the bacterium Enterococcus faecalis, which are relevant for water hygiene. By establishing the developed assay on the microarray analysis platform MCR 3, the automation of isothermal multiplex-amplification (39 °C, 40 min) and subsequent detection by chemiluminescence imaging was realized. Within 48 min, the microbes could be identified by the spot position on the microarray while the generated chemiluminescence signal correlated with the amount of applied microbe DNA. The limit of detection (LOD) determined for HAdV 41, Phi X 174, and E. faecalis was 35 GU/µL, 1 GU/µL, and 5 × 10(3) GU/µL (genomic units), which is comparable to the sensitivity reported for qPCR analysis, respectively. Moreover the simultaneous amplification and detection of DNA from all three microbes was possible. The presented assay shows that complex enzymatic reactions like an isothermal amplification can be performed in an easy-to-use experimental setup. Furthermore, iNAATs can be potent candidates for multipathogen detection in clinical, food, or environmental samples in routine or field monitoring approaches.


Subject(s)
Adenoviruses, Human/isolation & purification , Bacteriophage phi X 174/isolation & purification , Enterococcus faecalis/isolation & purification , Luminescent Measurements/instrumentation , Nucleic Acid Amplification Techniques/instrumentation , Oligonucleotide Array Sequence Analysis/instrumentation , Temperature
10.
J Virol Methods ; 193(2): 337-40, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23811231

ABSTRACT

Bovine coronavirus (BCoV) is an economically significant cause of calf scours and winter dysentery of adult cattle, and may induce respiratory tract infections in cattle of all ages. Early diagnosis of BCoV helps to diminish its burden on the dairy and beef industry. Real-time RT-PCR assay for the detection of BCoV has been described, but it is relatively expensive, requires well-equipped laboratories and is not suitable for on-site screening. A novel assay, using reverse transcription recombinase polymerase amplification (RT-RPA), for the detection of BCoV is developed. The BCoV RT-RPA was rapid (10-20 min) and has an analytical sensitivity of 19 molecules. No cross-reactivity with other viruses causing bovine gastrointestinal and/or respiratory infections was observed. The assay performance on clinical samples was validated by testing 16 fecal and 14 nasal swab specimens and compared to real-time RT-PCR. Both assays provided comparable results. The RT-RPA assay was significantly more rapid than the real-time RT-PCR assay. The BCoV RT-RPA constitutes a suitable accurate, sensitive and rapid alternative to the common measures used for BCoV diagnosis. In addition, the use of a portable fluorescence reading device extends its application potential to use in the field and point-of-care diagnosis.


Subject(s)
Cattle Diseases/diagnosis , Coronavirus Infections/veterinary , Coronavirus, Bovine/isolation & purification , Molecular Diagnostic Techniques/methods , Nucleic Acid Amplification Techniques/methods , Recombinases/metabolism , Reverse Transcription , Animals , Cattle , Cattle Diseases/virology , Coronavirus Infections/diagnosis , Coronavirus Infections/virology , Coronavirus, Bovine/genetics , Feces/virology , Nasal Cavity/virology , Point-of-Care Systems , Sensitivity and Specificity , Time Factors , Veterinary Medicine/methods , Virology/methods
11.
Trans R Soc Trop Med Hyg ; 107(3): 158-64, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23303802

ABSTRACT

BACKGROUND: Healthcare workers (HCW) are at risk of acquiring blood-borne viral infections, particularly hepatitis B (HBV), hepatitis C (HCV), and HIV, especially in high endemic regions such as sub-Saharan Africa. METHODS: Sera from 237 hospital workers in Southwest Cameroon were tested for anti-hepatitis B core antigen (anti-HBc), hepatitis B surface antigen (HBsAg), anti-hepatitis B surface antigen (anti-HBs), anti-HCV and (on a voluntary basis) for anti-HIV. Information on pre-study testing for HBV, HCV and HIV and pre-study HBV vaccination status was collected from these individuals. RESULTS: The pre-study testing rate among participating hospital staff for HBV was 23.6% (56/237), for HCV 16% (38/237), and for HIV 91.6% (217/237). The pre-study HBV vaccination rate was 12.3% (29/237). Analysis of anti-HBc revealed that 73.4% (174/237) of the hospital staff had been infected by HBV. Active HBV infection (HBsAg positivity) was detected in 15 participants. Anti-HCV was found in four of 237 participants, HIV antibodies were detected in four of 200 participants tested. CONCLUSION: HBV and HCV are neglected diseases among HCW in sub-Saharan Africa. The vaccination rate against HBV was very low at 12.3%, and therefore anti-HBc testing should be mandatory to identify HCW requiring HBV vaccination. Testing for HBV and routine HBV vaccination for HBV-negative HCW should be strongly enforced in Cameroon.


Subject(s)
Health Personnel/statistics & numerical data , Hepatitis B/epidemiology , Hepatitis C/epidemiology , Neglected Diseases/epidemiology , Adult , Aged , Antigens, Bacterial/blood , Cameroon/epidemiology , Cross-Sectional Studies , Female , HIV Infections/epidemiology , Hepatitis B/blood , Hepatitis B Antibodies/blood , Hepatitis C/blood , Hepatitis C Antibodies/blood , Humans , Male , Middle Aged , Multivariate Analysis , Neglected Diseases/blood , Occupational Exposure/adverse effects , Odds Ratio , Prevalence , Vaccination/statistics & numerical data , Young Adult
12.
J Gen Virol ; 92(Pt 8): 1906-1916, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21593276

ABSTRACT

Tick-borne encephalitis virus (TBEV) is the most important arboviral agent causing disease of the central nervous system in central Europe. In this study, 61 TBEV E gene sequences derived from 48 isolates from the Czech Republic, and four isolates and nine TBEV strains detected in ticks from Germany, covering more than half a century from 1954 to 2009, were sequenced and subjected to phylogenetic and Bayesian phylodynamic analysis to determine the phylogeography of TBEV in central Europe. The general Eurasian continental east-to-west pattern of the spread of TBEV was confirmed at the regional level but is interlaced with spreading that arises because of local geography and anthropogenic influence. This spread is reflected by the disease pattern in the Czech Republic that has been observed since 1991. The overall evolutionary rate was estimated to be approximately 8×10(-4) substitutions per nucleotide per year. The analysis of the TBEV E genes of 11 strains isolated at one natural focus in zdár Kaplice proved for the first time that TBEV is indeed subject to local evolution.


Subject(s)
Arachnid Vectors/virology , Encephalitis Viruses, Tick-Borne/classification , Encephalitis Viruses, Tick-Borne/genetics , Ixodes/virology , Phylogeny , Animals , Base Sequence , Czech Republic , Encephalitis Viruses, Tick-Borne/isolation & purification , Encephalitis, Tick-Borne/virology , Evolution, Molecular , Germany , Humans , Mice , Molecular Sequence Data , Phylogeography , Viral Proteins/genetics
13.
J Clin Microbiol ; 43(2): 808-12, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15695684

ABSTRACT

A survey of 158 rodents caught in the Czech Republic identified Dobrava virus sequences closely related to that of the Dobrava virus type strain in Apodemus sylvaticus and Mus musculus rodents. The identity of A. sylvaticus was unequivocally confirmed by random amplified polymorphic DNA analysis. The data seem to indicate hantavirus spillover from Apodemus flavicollis to other rodents.


Subject(s)
Hantavirus Infections/veterinary , Muridae/virology , Orthohantavirus/classification , Orthohantavirus/genetics , Reverse Transcriptase Polymerase Chain Reaction/methods , Rodent Diseases/transmission , Animals , Arvicolinae , Orthohantavirus/isolation & purification , Hantavirus Infections/virology , Mice , Molecular Sequence Data , Random Amplified Polymorphic DNA Technique , Rodent Diseases/virology , Sequence Analysis, DNA , Taq Polymerase/metabolism
15.
Bone Marrow Transplant ; 33(2): 243-5, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14716290

ABSTRACT

A 55-year-old man with acute myeloid leukemia in second relapse presented 4 months after haploidentical CD34+-selected hematopoietic stem cell transplantation (HSCT) with symmetric, progressive neurological deficits of the lower extremities. Although there was no molecular evidence for drug resistance in the cerebral-spinal fluid, antiviral combination therapy failed to control the rapidly progressing CMV polyradiculopathy (PRP) and encephalitis, which were confirmed by autopsy studies. Late CMV PRP as an unusual manifestation of CMV disease should be kept in mind in patients with suggestive neurological symptoms after HSCT.


Subject(s)
Cytomegalovirus Infections/complications , Hematopoietic Stem Cell Transplantation , Leukemia, Myeloid/therapy , Polyradiculopathy/virology , Acute Disease , Antigens, CD34/metabolism , Cytomegalovirus Infections/pathology , Fatal Outcome , Haploidy , Hematopoietic Stem Cells/metabolism , Humans , Male , Middle Aged , Polyradiculopathy/pathology
16.
Transplantation ; 72(7): 1325-7, 2001 Oct 15.
Article in English | MEDLINE | ID: mdl-11602864

ABSTRACT

BACKGROUND: The aim of this study was to evaluate pp65 antigen-guided antiviral therapy in preventing human cytomegalovirus (HCMV) infection in solid organ transplant recipients. METHODS: Ten kidney and two liver transplant recipients with asymptomatic HCMV infection were randomized either for i.v. ganciclovir or placebo treatment in a prospective, double-blind study. All patients were positive by HCMV pp65 antigen test at levels >5 positive cells/2 x 10(5) investigated cells. RESULTS: No cases of HCMV end-organ disease occurred. In contrast to patients on placebo (5/7), none of the patients on ganciclovir (0/5) developed HCMV-associated symptoms (P=0.01). However, because of the small number of patients, all three high-risk patients (donor seropositive, recipient seronegative) were randomized to placebo and all three developed symptoms. CONCLUSIONS: Preemptive antiviral therapy guided by the pp65 antigen test seems to have a beneficial effect on preventing HCMV-associated symptoms in kidney and liver transplant recipients.


Subject(s)
Antiviral Agents/therapeutic use , Cytomegalovirus Infections/prevention & control , Drug Delivery Systems , Ganciclovir/administration & dosage , Kidney Transplantation , Liver Transplantation , Phosphoproteins/therapeutic use , Viral Matrix Proteins/therapeutic use , Double-Blind Method , Ganciclovir/therapeutic use , Humans , Prospective Studies
17.
J Med Primatol ; 30(1): 14-9, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11396859

ABSTRACT

The aim of this study was to determine the prevalence of hepatitis B virus (HBV) infection in nonhuman primates. Serum samples from Europe, Thailand and Vietnam were analyzed. Sera obtained from 262 apes and 454 monkeys were tested for HBV infection serologically and for HBV DNA using nested PCR (nPCR). A total number of 198 ape sera and all but one (Cercopithecus aethiops) of the 4543 monkey sera had no serological signs of HBV infection. Among the 64 of 262 (24.4%) seropositive ape sera, we found, as in humans, different stages of HBV infection: very early HBV infection, active infection with high level of infectivity, virus carriers with low infectivity, and passed HBV infection. In the cases with passed infection, 47.8% harbored HBV DNA in the presence of protective antibodies to the HBV surface antigen (HBsAb). This indicates HBV persistence in apes despite immune control. In contrast to apes, in monkeys HBV infection is a very rare event.


Subject(s)
Haplorhini , Hepatitis B virus/pathogenicity , Hepatitis B/epidemiology , Hepatitis B/veterinary , Hominidae , Animals , Antibodies, Viral/analysis , DNA, Viral/analysis , Humans , Polymerase Chain Reaction , Prevalence , Serologic Tests
18.
J Virol ; 74(11): 5377-81, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10799618

ABSTRACT

We characterized hepatitis B virus (HBV) isolates from sera of 21 hepatitis B virus surface antigen-positive apes, members of the families Pongidae and Hylobatidae (19 gibbon spp., 1 chimpanzee, and 1 gorilla). Sera originate from German, French, Thai, and Vietnamese primate-keeping institutions. To estimate the phylogenetic relationships, we sequenced two genomic regions, one located within the pre-S1/pre-S2 region and one including parts of the polymerase and the X protein open reading frames. By comparison with published human and ape HBV isolates, the sequences could be classified into six genomic groups. Four of these represented new genomic groups of gibbon HBV variants. The gorilla HBV isolate was distantly related to the chimpanzee isolate described previously. To confirm these findings, the complete HBV genome from representatives of each genomic group was sequenced. The HBV isolates from gibbons living in different regions of Thailand and Vietnam could be classified into four different phylogenetically distinct genomic groups. The same genomic groups were found in animals from European zoos. Therefore, the HBV infections of these apes might have been introduced into European primate-keeping facilities by direct import of already infected animals from different regions in Thailand. Taken together, our data suggest that HBV infections are indigenous in the different apes. One event involving transmission between human and nonhuman primates in the Old World of a common ancestor of human HBV genotypes A to E and the ape HBV variants might have occurred.


Subject(s)
Genetic Variation , Hepatitis B virus/genetics , Hepatitis B/veterinary , Monkey Diseases/virology , Animals , Genome, Viral , Hepatitis B/virology , Hepatitis B Surface Antigens/genetics , Hepatitis B virus/classification , Hepatitis B virus/isolation & purification , Humans , Hylobates , Primates , Protein Precursors/genetics , Sequence Analysis, DNA , Viral Envelope Proteins/genetics
19.
J Infect Dis ; 180(5): 1695-9, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10515835

ABSTRACT

To estimate the frequency of persistent Borna disease virus (BDV) infections of the human central nervous system and to determine which neuropsychiatric disorders might be associated with this viral infection, reverse transcription-nested polymerase chain reaction was used to screen a large collection of autopsy brain samples for the presence of BDV-specific nucleic acids. The presence of BDV RNA was found in 3 brains of persons with psychiatric symptoms and prominent hippocampal degeneration previously reported to be positive by others. However, no BDV RNA was detected in 86 randomly collected brains from persons with various psychiatric disorders, including schizophrenia, affective disorders, and Alzheimer's disease, or from suicide victims or in 52 brains from healthy controls. Furthermore, no BDV-RNA was detected in 16 surgical brain samples from persons with epilepsy-associated hippocampal sclerosis. These results indicate that life-long persistent BDV infections are rare in humans and that such infections may be associated with certain forms of hippocampal degeneration.


Subject(s)
Borna Disease/complications , Borna disease virus/isolation & purification , Brain/virology , Hippocampus , Mental Disorders/virology , Neurodegenerative Diseases/virology , Adult , Aged , Aged, 80 and over , Borna Disease/virology , Borna disease virus/genetics , Epilepsy/complications , Female , Hippocampus/pathology , Hippocampus/virology , Humans , Male , Mental Disorders/complications , Middle Aged , Neurodegenerative Diseases/complications , RNA, Viral/analysis , Reverse Transcriptase Polymerase Chain Reaction , Sclerosis
20.
J Gen Virol ; 80 ( Pt 6): 1495-1500, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10374968

ABSTRACT

Human cytomegalovirus (HCMV) strains can be classified into different glycoprotein B (gB) genotypes. In a previous study, frequent intragenic variation of the gB gene was shown. The aim of this study was to analyse whether gB variation was due to homologous recombination. The gB gene of DNA extracts derived from the peripheral blood leukocytes of 14 immunosuppressed patients was amplified by PCR and cloned. Three variable sites of gB were analysed by restriction fragment analysis and DNA sequencing and compared with published prototypic strains. In three patients doubly infected with two distinct HCMV gB strains, prototypic (60-85%) and non-prototypic recombinant strains (5-40%) were detected. To demonstrate that homologous recombination is driving HCMV gB variability, cells were coinfected with plaque-purified prototypic gB strains and recombinant gB genes were selectively amplified by PCR. gB recombinants were detected after 15 days of coculture and cross-over sites were determined by sequencing. These data indicate that homologous recombination contributes to the variability of the gB gene in vitro and in vivo.


Subject(s)
Cytomegalovirus Infections/virology , Cytomegalovirus/genetics , Genetic Variation , Recombination, Genetic , Viral Envelope Proteins/genetics , Cell Line , Crossing Over, Genetic , Cytomegalovirus/classification , Genes, Viral , Genotype , Humans , Immunosuppression Therapy , Polymerase Chain Reaction/methods , Sequence Analysis, DNA , Viral Envelope Proteins/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...